P1.01-64 Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLCM. Marmarelis,E. Bange,Stephen J. Bagley,W. Hwang,Y. Yang,Jeffrey C. Thompson,Joshua Bauml,Christine Ciunci,Evan W. Alley,J. Morrissette,Roger B. Cohen,Corey J. Langer,E. Carpenter,Charu AggarwalJOURNAL OF THORACIC ONCOLOGY（2018）引用 1|浏览70暂无评分关键词Immunotherapy,STK11,TP53AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
